Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
S.R. Targan, S.B. Hanauer, S.J. Van Deventer, L. Mayer, D.H. Present, T. Braakman, et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group.
N Engl J Med, 337 (1997), pp. 1029-1035
[2.]
F.J. Baert, G.R. D’Haens, M. Peeters, M.I. Hiele, T.F. Schaible, D. Shealy, et al.
Tumor necrosis factor a antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis.
Gastroenterology, 116 (1999), pp. 22-28
[3.]
R.D. Cohen, J.F. Tsang, S.B. Hanauer.
Infliximab in Crohn’s disease: first anniversary clinical experience.
Am J Gastroenterol, 95 (2000), pp. 3469-3477
[4.]
R.J. Farrell, S.A. Shah, P.J. Lodhavia, M. Alsahli, K.R. Falchuk, P. Michetti, et al.
Clinical experience with infliximab therapy in 100 patients with Crohn’s disease.
Am J Gastroenterol, 95 (2000), pp. 3490-3497
[5.]
E. Ricart, R. Panaccione, E.V. Loftus, W.J. Tremaine, W.J. Sandborn.
Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients.
Am J Gastroenterol, 96 (2001), pp. 722-729
[6.]
G.R. Lichtenstein.
Treatment of fistulizing Crohn’s disease.
Gastroenterology, 119 (2000), pp. 1132-1147
[7.]
D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. Van Hogezand, et al.
Infliximab for the treatment of fistulas in patients with Crohn’s disease.
N Engl J Med, 340 (1999), pp. 1398-1405
[8.]
S. Schreiber, M. Campieri, J.F. Colomberl, S.J.H. Van Deventer, B. Feagan, R. Fedorak, et al.
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.
Int J Colorectal Dis, 16 (2001), pp. 1-11
[9.]
I. Rasul, S.R. Wilson.
Infliximab therapy for Crohn’s disease fistulae: discordance between perineal ultrasound findings and clinical response.
Gastroenterology, 120 (2001), pp. A619
[10.]
R.D. Cohen, P. Papalia, S.B. Hanauer.
Infliximab is steroid-sparing in luminal Crohn’s disease.
Gastroenterology, 120 (2001), pp. A620
[11.]
S.B. Hanauer, G.R. Lichstenstein, J-F. Colombel, L. Mayer, S. Schreiber, D. Rachmilewicz, et al.
Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn’s disease: preliminary results from the ACCENT I trial.
Gastroenterology, 120 (2001), pp. A21
[12.]
J.S. Hyams, J. Markowitz, R. Wyllie.
Use of infliximab in the treatment of Crohn’s disease in children and adolescents.
J Pediatr, 137 (2000), pp. 192-196
[13.]
S. Kugathasan, S.L. Werlin, A. Martinez, M.T. River, J.B. Heikenen, D.G. Binion.
Prolonged durantion of response to infliximab in early but not late pediatric Crohn’s disease.
Am J Gastroenterol, 95 (2000), pp. 3189-3194
[14.]
S. Khan, W.A. Henderson, S.A. Kocoshis, A. Goyal, C. Di Lorenzo.
The use of infliximab in pediatric Crohn’s disease.
Gastroenterology, 120 (2001), pp. A210
[15.]
T. Andus, H. Herfarth, F. Obermeier, T. Kuehbacher, S. Mascheretti, W. Thriene, et al.
Improvement of arthritis/arthralgia after treatment with infliximab (remicade) in a german prospective open-label multicenter trial in refractory Crohn’s disease.
Gastroenterology, 120 (2001), pp. A621
[16.]
F. Van den Bosch, E. Kruithof, D. Baeten, F. De Keyser, H. Mielants, E.M. Veys.
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in espondyloarthropaty: an open pilot study.
Ann Rheum Dis, 59 (2000), pp. 428-433
[17.]
F.L. Jacksonville, M.R. Fleisher, S.D. Rubin, M. Sasson, J. Zlatanic, A. Burns, et al.
Remicade in the treatment of refractory extraintestinal manifestations of Crohn’s disease.
Gastroenterology, 120 (2001), pp. A620
[18.]
E. Ricart, R. Panaccione, E. Loftus, W.J. Tremaine, W.J. Sandborn.
Successful management of Crohn’s disease of the ileoanal pouch with infliximab.
Gastroenterology, 117 (1999), pp. 429-432
[19.]
S.J. Bickston, G.R. Lichtenstein, K.O. Arseneau, R.B. Cohen, F. Cominelli.
The relationship between infliximab treatment and lymphoma in Crohn’s disease.
Gastroenterology, 117 (1999), pp. 1433-1437
[20.]
T.M. Remicade.
(infliximab). Prescribing information.
[21.]
S. Vermeire, M. Noman, G. Van Assche, N. Esters, S. Joossens, F. Baert, et al.
Infliximab (Remicade) treatment in Crohn’s disease and antinuclear antibody (ANA) formation.
Gastroenterology, 120 (2001), pp. A69
[22.]
E. Garcia-Planella, E. Domènech, E. Esteve-Comas, I. Bernal, V. Lorenzo-Zúñiga, M.A. Alvarez, et al.
Positivización de anticuerpos antinucleares en pacientes con enfermedad de Crohn tratados con infliximab y su repercusión clínica.
Gastroenterol Hepatol, 24 (2001), pp. 170
[23.]
J.A. Katz, G.R. Lichtenstein, G.F. Keenan, D.E. Healy, S.J. Jacobs.
Outcome of pregnancy in women receiving RemicadeTM (infliximab) for the reatment of Crohn’s disease or rheumatoid arthritis.
Gastroenterology, 120 (2001), pp. A69
[24.]
D.S. Feffeman, P.J. Lodhavia, S. Reinert, M. Alsahli, A. Hani, K.R. Falchuk, et al.
Smoking, age, duration of disease, gender, and other clinical factors do not predict response to infliximab in Crohn’s disease.
Gastroenterology, 120 (2001), pp. A619
[25.]
P. Rutgeerts, G. D’Haens, S. Targan, E. Vasiliauskas, S.B. Hanauer, D.H. Present, et al.
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease.
Gastroenterology, 117 (1999), pp. 761-769
[26.]
J.M. Kremer.
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
Ann Intern Med, 134 (2001), pp. 695-706
[27.]
R.J. Farrell, M. Alsahli, K.R. Falchuk, M.A. Peppercorn, P. Michetti.
Human anti-chimeric antibody levels correlate with lack of response and infussion reactions following infliximab therapy.
Gastroenterology, 120 (2001), pp. A69
[28.]
G.R. D’Haens, R. van Hogezand, J. Kisiel, S.J.H. van Deventer, K.L. De Woody, T.F. Schaible, et al.
Duration of response following cessation of infliximab therapy for active or fistulizing Crohn’s disease.
Gastroenterology, 116 (1999), pp. A3029
[29.]
L.Y. Kam, E.A. Vasiliauskas, M.T. Abreu, P.V. Hassard, A. Kalenich, J. Gaiennie, et al.
Attenuation of response to multiple retreatment infliximab infusions for active Crohn’s disease potential factors that minimize decreased response.
Gastroenterology, 118 (2000), pp. A655
[30.]
S. Nikolaus, A. Raedler, T. Kuhbacher, N. Sfikas, U.R. Folsch, S. Schreiber.
Mechanisms in failure of infliximab for Crohn’s disease.
Lancet, 356 (2000), pp. 1475-1479
[31.]
R.D. Cohen.
Efficacy and safety of repeated infliximab infusions for Crohn’s disease: 1-year clinical experience.
Inflammatory Bowel Dis, 7 (2001), pp. 17-22
[32.]
M. Noman, F. Baett, G. D’Haens, G. Van Assche, C. Swijsen, I. Aerden, et al.
HACA formation after infliximab treatment in Crohn’s disease is clearly associated with infusion reactions.
Gastroenterology, 120 (2001), pp. A62
[33.]
R. Petroniene, J.P. Baker, B.C.R. Crosara-Winter, C.A. Ottaway, T.L. Moore, J.J. Connon, et al.
Infusion related reactions to anti-TNFá chimeric monoclonal antibody, RemicadeTM, can be abrogated by premedication: one site’s expereince.
Gastroenterology, 120 (2001), pp. A620
[34.]
G. Van Assche, D. Vanbeckevoort, D. Bielen, G. Coremans, I. Aerden, M. Noman, et al.
MRI imaging of the effects of infliximab in perianal fistulizing Crohn’s disease.
Gastroenterology, 120 (2001), pp. A68
[35.]
J.J. Hong, N.H. Merel, S.B. Hanauer.
Treatment of pyoderma gangrenosum complicating Crohn’s disease with infliximab.
Gastroenterology, 120 (2001), pp. A621
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
